Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

Pre-Filled Syringes West Coast ... critical processes in design of combination products and implications in scaling up with David Post (AbbVie); Navigating injection technologies for reliable ...

ATTENDEE LIST RELEASED – full version is available on the Download Centre of the Pre-Filled Syringes West Coast website. A snap shot of those confirmed attendance: AbbVie, Allergan, Amgen ...

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

Looking at AbbVie's filings since the merger, total cumulative sales from Allergan products since 2020 eclipsed $65 billion this year, per my calculation. And obviously, there is much more to come.

Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of ...

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

A splashy recent acquisition by the company might not be panning out. Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary ...

Emraclidine was part of AbbVie's acquisition of Cerevel last year, which also included Tavapadon, which reported positive Phase 3 data. Bristol's Cobenfy is now poised to dominate the ...